Concepedia

Author

Eileen Liao

Dana-Farber Cancer InstituteORCID

Also Known As

E. Liao, Eileen L. Liao, Eileen Liao

23

Publications

497

Citations

7

H-Index

8

Concepts

All Affiliations

Dana-Farber Cancer InstituteSarah CannonMillennium Engineering and Integration (United States)Takeda (United States)Mayo Clinic in Florida
EL

About

Eileen Liao is an author at Dana-Farber Cancer Institute specializing in clinical trials, radiation oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

260

2

Medicine

1

1

260

3

Immunology

1

1

260

4

Clinical Trials

1

1

260

5

Hematology

1

1

260

Eileen Liao

×

7

Publications

474

Citations

7

H-Index

YearCitations

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky,

The Lancet Oncology

2014

260

Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With <i>RPGR</i> Gene Variations

Lenore von Krusenstiern, Jiajun Liu, Eileen Liao,

JAMA Ophthalmology

2023

56

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky,

Leukemia

2019

48

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma

Paul G. Richardson, Craig C. Hofmeister, Cara A. Rosenbaum,

British Journal of Haematology

2018

34

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Paul G. Richardson, Craig C. Hofmeister, Cara A. Rosenbaum,

Blood

2013

31

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky,

Blood

2014

28

Resveratrol regulates the silent information regulator 1–nuclear factor‐κB signaling pathway in intrahepatic cholestasis of pregnancy

Eileen Liao, Zhizun Li, Yong Shao

Hepatology Research

2018

17

Page 1